Cardium Therapeutics Inc Share Price Nyse
Equities
US1419161062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 43.45M |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 88.47M | Net Debt 2020 | 874K 69.01M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 21/12/03 | |
James Grainer
CHM | Chairman | 69 | 21/05/20 |
Lois Chandler
COO | Chief Operating Officer | - | 30/06/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 21/12/03 | |
James Grainer
CHM | Chairman | 69 | 21/05/20 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 21/05/20 |
1st Jan change | Capi. | |
---|---|---|
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |